SCHEMBL4492841

SCHEMBL4492841

O=C(c1nc(O)c(O)c2c1CCN(Cc1ccc(F)cc1)C2=O)N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.42
PIK3CD O00329 4/20 0.40
PIK3CA P42336 4/20 0.40
PIK3CB P42338 4/20 0.40
PIK3R2 O00459 3/20 0.40
PIK3CG P48736 3/20 0.40
PIK3R5 Q8WYR1 3/20 0.40
PIK3R3 Q92569 3/20 0.40
ALDH1A1 P00352 4/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
AKR1B1 P15121 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4479852 0.91 AKR1B1 (0.41) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A
SCHEMBL13672792 0.84 AKR1B1 (0.43) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A
SCHEMBL4479990 0.80 OPRM1 (0.41) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A
SCHEMBL4502978 0.79 AKR1B1 (0.39) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A
SCHEMBL4490458 0.78 AKR1B1 (0.39) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A
SCHEMBL4483672 0.77 AKR1B1 (0.38) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A
SCHEMBL4490374 0.77 AKR1B1 (0.38) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A
SCHEMBL4206283 0.75 MEN1 (0.45) SMN1; SMN2PIK3CDPIK3CAPIK3CBPIK3R2
SCHEMBL10233489 0.75 GPR52 (0.40) PIK3CDPIK3CAPIK3CBAKR1B1
SCHEMBL4480533 0.74 LMNA (0.39) SMN1; SMN2ALDH1A1AKR1B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
WO-2005087767-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H SMN1; SMN2 4492/4885PIK3CD 139/4885PIK3CA 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.